Thursday, October 12, 2017 8:06:56 PM
Analyst Jim Birchenough is bullish on the company following selection of IPI-549 monotherapy data as a late breaker oral presentation at SITC annual meeting next month. The analyst comments "Based on prior SITC late breaker data we see a reasonable likelihood of proof-of-concept response rate data, and with likely validation of tumor macrophage targeting in immunooncology (IO) and a unique mechanism of action we see upside potential not reflected at current stock price."
New York Yankees and Duke Basketball
FEATURED POET Announces Design Win and Collaboration with Foxconn Interconnect Technology for High-speed AI Systems • May 14, 2024 10:09 AM
FEATURED Element79 Gold Corp Reports Exceptionally High-Grade Results from Lucero • May 14, 2024 7:00 AM
VAYK Added New Manager for Expansion into $64 Billion Domestic Short-term Rental Market • VAYK • May 14, 2024 9:00 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM